Palliative Care Study in Patients With Advanced Cancer

NCT ID: NCT00127517

Last Updated: 2011-06-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31
• Study Completion Date: 2006-08-31

Brief Summary

The purpose of this study is to determine whether patients with advanced cancers who receive AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain; improved mood; and decreased fatigue. For the first three weeks, some patients receive AVR118, and others receive placebo (an injection expected to have no benefits). After three weeks, all patients will be offered the opportunity to take injections of AVR118.

Detailed Description

Advanced cancers are usually debilitating. There are few treatments available for symptoms of advanced cancers like loss of appetite, decreased strength, fatigue, and change in mood. A Phase II, double blind study comparing treatment with AVR118 to placebo, followed by an open label phase treating all patients with AVR118, will enable the Sponsor to gather data on safety and efficacy of AVR118 in this patient population. Patients aged 18-80 with advanced cancers (excluding central nervous system [CNS] cancers) who are not receiving chemotherapy, or who are receiving single agent, third line (or beyond) chemotherapy, may be eligible to participate.

Conditions

Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

peptide-nucleic acid solution AVR118

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• · Histologically confirmed malignancy (excluding central nervous
• system malignancy)
• · Not a candidate for, or refuses, curative anti-neoplastic therapy.
• · Between the ages of 18 and 80.
• · Symptoms of advanced cancer (loss of appetite, fatigue, weakness,
• malaise) that are not attributed to anemia, concomitant illnesses, or
• obstruction or loss of organ function.
• · Karnofsky performance status of ³40%, _<_ 80%.
• · Normal cognition, interpreted as a Mini-Mental State Score of at
• least 20.
• · Life expectancy of >4 months.
• · Decrease in weight of at least 5% over the preceding 6 months, with
• no weight gain over the most recent 30 days
• · Pretreatment laboratory data within 7 days of enrollment (if
• screening labs are done within 3 days of Day 1, they need not be
• repeated on Day 1).
• ¨ Hemoglobin >8.5 g/dL on no, or on stable doses (hematocrit stable
• within 1 gram and dose stable for one month) of Epogen or similar
• medication.
• ¨ Absolute neutrophil count (ANC) ³1,500/mm^3 .
• ¨ Platelets ³50,000/mm^3 .
• ¨ Total bilirubin £1.5 the upper limit of normal (ULN).
• ¨ ALT and AST £2.5 times the ULN, or, if the patient has liver
• metastases, £5 times the ULN.
• ¨ Creatinine £1.5 mg/dL.
• ¨ Fasting blood sugar -<1.2 x ULN
• ¨ Normal T3, T4, TSH
• · Voluntary written informed consent before performance of any
• study-related procedure that is not part of normal medical care.
• · Ability to self-administer subcutaneous medication, or to have an
• assistant who can administer the study medication according to the
• protocol.
• · Female patient is post-menopausal, surgically sterilized, or willing
• to use acceptable methods of birth control (i.e., a hormonal
• contraceptive, intra-uterine device, diaphragm with spermicide, or
• condom with spermicide, or abstinence) for the duration of the study.
• · Male patient agrees to use an acceptable barrier method for
• contraception during the study.
• · If on an antidepressant, the dose must have been stabilized for at
• least 60 days

Exclusion Criteria

• · Received immunotherapy, radiation therapy or experimental therapy
• within three weeks.
• · Receiving chemotherapy other than third-line, single agent therapy;
• permitted third-line, single agent dose must be stable for at least
• one month.
• · Diabetes requiring insulin or oral hypoglycemic agents.
• · Mechanical reason to be unable to eat, or is reasonably expected to
• develop an obstruction during the next eight weeks
• · Myocardial infarction within six months of enrollment.
• · Uncontrolled brain metastases or central nervous system disease.
• · Major surgery within four weeks of enrollment.
• · Severe allergies to milk or milk products.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Advanced Viral Research Corp

INDUSTRY

Sponsor Role: lead

Locations

Medical Center of Vincennes

Vincennes, Indiana, United States

Queens Medical Associates

Fresh Meadows, New York, United States

Jacobi Medical Center

The Bronx, New York, United States

Countries

United States

Other Identifiers

AVR118 04-002

Identifier Type: -

Identifier Source: org_study_id